S tent implantation is a common percutaneous coronary intervention (PCI) procedure. Although the rate of adverse events after a procedure has been minimized with modern techniques, stent thrombosis (ST) remains a significant concern. The incidence of ST varies with the patient population, treatment assignment, and duration of follow-up; estimates report that the 1-year incidence of definite ST ranges from 0.1% to 3%, 1-9 with the majority of events occurring within 30
days. 10 Although relatively uncommon, ST is associated with an increased occurrence of death, myocardial infarction (MI), and major adverse cardiac events. 1, [11] [12] [13] [14] [15] [16] [17] [18] [19] Because of this uncommon yet serious adverse event, ST plays a significant role as a safety and efficacy end point for many cardiovascular trials involving stenting during PCI. 20 Angiographic core laboratories (ACLs) and clinical event committees (CECs) are often used in clinical trials to provide an independent and blinded analysis of events and end points. Stringent definitions have been developed to address the uncertainty surrounding possible ST end point events. 20 Although discrepancies are known to exist between the central review groups and local investigators (LIs), [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] the degree to which CEC adjudication of events (using hospital source documents) is concordant with the review of an independent ACL (evaluating the actual readings) has not yet been established. The present substudy provides the first assessment of interobserver variability between these groups. In this subanalysis of the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRACER), angiograms of patients meeting the substudy entry criteria for possible ST were examined by an ACL, and the agreement between the ACL, CEC, and LIs was evaluated.
Methods

The TRACER Trial
TRACER was a prospective, randomized, double-blind, multicenter, phase III trial of 12 944 patients designed to assess the safety and efficacy of the novel platelet protease-activated receptor-1 inhibitor vorapaxar. Moderate-to high-risk patients presenting with a clinical manifestation of non-ST-segment-elevated acute coronary syndrome were randomized to standard of care therapy plus either vorapaxar or placebo. The study was approved by the appropriate national and institutional regulatory authorities and ethic committees, and all subjects gave informed consent.
The primary efficacy end point was a composite of cardiovascular death, MI, stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization. Ischemia was defined as cardiac ischemia-related symptoms lasting ≥10 minutes within 24 hours before initial presentation (including subjects already in the hospital for another, unrelated condition). Secondary end points included allcause death; a composite of cardiovascular death, MI, and stroke; and the singular outcomes included in the primary end point. Safety end points included a composite of moderate and severe Global Use of Strategies to Open Occluded Arteries (GUSTO) bleeding events and Thrombolysis In Myocardial Infarction (TIMI) clinically significant bleeding. In addition to all efficacy and safety end point events, a CEC also adjudicated cases of ST.
Inclusion Criteria for ST Substudy
An effort to validate findings of CEC-adjudicated ST was planned during the course of the trial. This consisted of central and independent review from an ACL of angiograms from patients who were treated with PCI during index hospitalization and had a clinical suspicion of angiographically confirmed ST. For the purposes of this substudy, patients who underwent stenting during the index PCI procedure were included into the cohort of potential ST if they met one of the following criteria: (1) any ST diagnosis reported by LIs in the electronic case report form (eCRF); (2) any CEC-confirmed Academic Research Consortium (ARC) definite ST after the index procedure; or (3) any PCI reported as urgent by the LI after the index PCI with an MI or ischemia leading to urgent coronary revascularization confirmed by the CEC≤7 days before the urgent PCI. It was felt that the chance of angiographically confirmed ST in TRACER patients managed with PCI during acute coronary syndrome event would have been low among those who did not meet the above criteria. In all patients who were identified using these criteria, LIs were contacted to send relevant angiographies to the ACL. In addition to the ST events identified using these criteria, additional events, not meeting the 7-day window of inclusion criteria for this study, were also examined for ST and reported in a separate analysis.
It is important to note that LIs reported stent thromboses from the evaluation of their patients' angiograms, which may be considered the equivalent of CEC-reported ARC definite ST and ACL-confirmed ST. This allowed for comparisons among these groups.
CEC Methods
All suspected cases of death, MI, urgent coronary revascularization, and recurrent ischemia with rehospitalization-which were reported by the investigator or identified through other key data elements collected in the eCRFs-were also adjudicated by the CEC with respect to ST using both the ARC and TIMI definitions (Appendices I and II in the Data Supplement). The source documentation included laboratory values, eCRFs, catheterization laboratory and discharge reports, and event summaries. However, angiographic films were not used in CEC adjudication. For this substudy, only events adjudicated as ARC definite were considered to be identified by the CEC. ARC definite ST requires either angiographic or pathological confirmation. Events categorized by the CEC as ARC probable or ARC possible were treated as although the CEC did not identify ST.
Angiographic Analysis Methods
The PERFUSE core laboratory served an ACL for the TRACER subanalysis and performed all independent reading of collected angiographies. Baseline angiographic cinefilms (index procedure) and any available subsequent angiograms meeting the inclusion criteria were sent to the ACL for analysis. The ACL did not have any access to clinical data during the adjudication process. The index cinefilms were analyzed to determine the site of stent implantation even if the stent could not be visualized at the site of a thrombus. The nature of the new culprit lesion was categorized as target vessel, target lesion, or nontarget vessel revascularization. Flow and perfusion in the culprit artery were evaluated before PCI using the TIMI flow grade 41 and myocardial perfusion grade. 42 The presence or absence of a stent thrombus, originating in the stent or in the segment 5 mm proximal or distal to it, was noted for all cases. This was defined as ACL-confirmed ST, the equivalent of ARC definite ST reported by the CEC. TIMI thrombus grade 43 was also assessed. Location of the thrombus was recorded both relative to the
WHAT IS KNOWN
• ST is an important end point in cardiovascular clinical trials that may be reported by LIs and adjudicated by a CEC.
• There are known discrepancies between central review groups and LIs when reporting possible ST events, but the concordance between a CEC that uses source documents versus an ACL that evaluates actual angiographic readings has not been studied.
WHAT THE STUDY ADDS
• The degree of concordance between the LI, the CEC, and the ACL is moderate.
• The assessment of ST is more often detected by direct review of angiograms by an ACL. stent location and relative to the coronary artery anatomy. Each film was initially reviewed by 2 experienced angiographers at the ACL. All films were over-read by an experienced interventional cardiologist with >25 years of experience reviewing acute coronary syndrome films (C.M.G.).
Objectives and Statistical Considerations
The main goals were to compare reporting of ST by the LIs versus the CEC and ACL. Furthermore, we aimed to directly compare the adjudication of ST performed by the CEC versus the ACL. For the purpose of this analysis, CEC-confirmed ST events were considered as those classified as ARC definite. Finally, although the main TRACER analysis was based on CEC-adjudicated data, we aimed to explore the efficacy of vorapaxar using ACL-determined ST.
For the statistical analyses, all continuous values are reported as means (SDs), medians (interquartile ranges), and ranges (minimum to maximum). Categorical variables are summarized as frequencies (percentages). A P value of <0.05 was considered statistically significant. The κ statistic was used to compare agreement between the LI, ACL, and CEC. A value of κ=1 implies perfect agreement, and a value of κ=0 implies the parties agreed no better than by chance alone. Estimates of the hazard ratios and 95% confidence intervals (CIs) for vorapaxar versus placebo were calculated via a Cox proportional hazards model in which study-group assignment and stratification factors were included as covariates. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Of the 12 944 patients randomized in TRACER, 7075 underwent stenting during index PCI. Before database lock, 457 patients satisfied the substudy's inclusion criteria; of these, angiographic films of 331 patients could be obtained and were provided to the ACL for review. The ACL successfully analyzed 329 of these subjects (Figure 1 ). There were no significant differences in baseline characteristics between patients who had an angiogram for review and those who did not. The baseline characteristics of patients included in the present analysis (Appendix III in the Data Supplement) were similar to those previously reported for the TRACER study. 
LI-Reported and ACL-Confirmed ST
The LIs and ACL agreed on the presence of ST in 81 events and the absence of it in 120 events ( Table 2 ). The ACL identified 27 events not reported by LIs and did not find angiographic evidence of ST in 101 events reported by LIs. Overall, LIs and the ACL agreed on the presence/absence of ST in 61.1% of events included in the substudy, and agreement between these groups was κ=0.25 (95% CI, 0.16-0.34).
CEC-Adjudicated ARC Definite and ACL-Confirmed ST
The CEC and ACL agreed on the presence of ST in 61 events and the absence of it in 211 events ( Table 3 ). The ACL identified 47 cases of ST that were not identified as ARC definite ST by the CEC. The ACL was also unable to find angiographic evidence of ST in 10 CEC-identified ARC definite stent thromboses. Overall, the ACL and CEC agreed on the presence/absence of ST in 82.7% of events, and agreement between these groups was κ=0.57 (95% CI, 0.47-0.67).
Effect of ACL Confirmation on Frequency of ST
The rate of ST did not differ significantly between patients randomized to vorapaxar or placebo ( 
Discussion
This study provides the first assessment of interobserver variability among LIs, a CEC, and an ACL and demonstrates limited agreement among these groups in determining the presence of ST. The ability of a CEC to adjudicate possible ST events using the ARC criteria may have been limited insofar because only written materials and no primary data from angiograms are submitted for interpretation. Although evaluation by the ACL resulted in numerically different event rates between vorapaxar and placebo groups, which was not observed using CEC-only data, the difference was not statistically significant, and the results of the trial were not altered. However, given that nearly one-third of the intended cohort had missing angiograms and the wide CIs, we could not confirm whether the rate of ACL-confirmed ST would be statistically different between vorapaxar and placebo had all the intended angiograms been collected.
Agreement Between LIs and the ACL
A variety of rigorous angiographic definitions and scores have been developed to minimize variability and allow cross-study comparison. [20] [21] [22] 41, 43, 45 Several studies have demonstrated only moderate agreement between ACLs and LIs in the assessment of quantitative and semiquantitative angiographic measures, including the TIMI flow grade 22 and the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score. 21, 23, 24 Substantial agreement between core laboratories and LIs has been reported for other semiquantitative measures, such as ST-segment-elevation on electrocardiograms 25, 26 or perfusion defects on single photon emission computed tomography and positron emission tomography. 27, 28 However, at least 1 study Cohen κ coefficient κ=0.25 (95% CI, 0.16-0.34). Data presented as n (% of row total) and (% of column total). ACL indicates angiographic core laboratory; CI, confidence interval; and LI, lead investigator. 46 The agreement for qualitative measures, such as the presence of thrombus, has been weaker as well. 21, 29, 30 Indeed, the limited agreement in this study is consistent with previously reported agreement in the assessment of thrombus 29 and suggests that at least one source of interobserver variability may be because of the assessment of thrombus. Compared with LIs, who may clinically observe ST in 1% to 2% of patients, an ACL may be more likely to rigorously apply strict definitions to determine the presence/absence of ST.
Agreement Between LIs and the CEC
This is the first comparison between CEC-adjudicated and LI-reported ST. The CEC and LIs agreed on the presence/ absence of ST in only 62.0% of events in the substudy. This rate of agreement is lower than that reported for MI, 31, 32, 34, 35 heart failure, 33, 37 hospitalization, 38 and death. 38, 39 The standard CEC review of ST, which was also done in TRACER, consists of reviewing data from the eCRF and source clinical documents provided by the LI, including catheterization laboratory reports. Therefore, the CEC mostly relies on catheterization laboratory reports for determining whether a ST occurred. However, the final catheterization report is not perceived by several groups to be as accurate as the LI assessment on an eCRF. The discrepancies in what was included in the catheterization report and what was entered into the eCRF may have contributed to the number of events reported by the LIs and not the CEC.
Agreement Between the CEC and ACL
Slightly better agreement, however, was found between the CEC and the ACL (82.7%). These results represent the first published data on the agreement between an ACL and a CEC.
The ACL was not able to find angiographic evidence of ST in 10 of the 71 ARC definite ST cases adjudicated by the CEC and identified another 47 events outside of what was reported by the CEC.
Several trials have reported that the use of centrally adjudicated or core laboratory data has produced differing results compared with LI-reported data. 32, 34, 36, 40 Several studies have demonstrated that identification of events by a CEC or core laboratory is more closely associated with subsequent adverse events versus LI-identified events identified. 25, 26, 35, 46 Although including ACL readings in the CEC-adjudication process may have modestly impacted this study's outcome, the underreporting in eCRFs could obscure a potential reduction in ST in future trials.
The reason for lack of agreement among the CEC, ACL, and LIs was not investigated in this study. At least 1 study has demonstrated that after LIs were informed of the rationale behind an adjudication committee's decision to reclassify an event, most agreed with the committee. 34 Possible explanations for the limited agreement between the LIs and the CEC and between the LIs and the ACL include decreased interobserver variability at the CEC and ACL, reduced familiarity with the ARC criteria, differences in clinical and ARC-based definitions, and underreporting of event details in source documents.
A review of the documents made available to the TRACER CEC during adjudication supports the possibility of underreporting in the source documentation. In addition to the 329 events reviewed by the ACL, an additional 18 events, not meeting the 7-day window of inclusion criteria for this study, were also examined for ST. A total of 116 events (108 included in this analysis and 8 additional events) were identified by the ACL as meeting the criteria for ST. These cases were reviewed by an experienced adjudicator (P.T.) to examine the information provided to the CEC. Of the 116 cases, documentation of 1 event was not available for review. The reviewer confirmed that the initial adjudication of the 115 cases by the CEC was consistent with the information provided in the source documentation (Appendix IV in the Data Supplement). Notably, of the 54 discordant cases between the CEC and ACL, 37 had catheterization laboratory reports available that did not provide sufficient evidence to meet the ARC definite criteria for ST.
Adjudication of ST by CECs using ARC criteria seems to be reproducible. In an analysis of 100 events, including 48 ST events and 26 ARC definite ST events, no discordance Cohen κ coefficient κ=0.57 (95% CI, 0.47-0.67). Data presented as n (% of row total) and % (% of column total). ACL indicates angiographic core laboratory; ARC, Academic Research Consortium; CEC, clinical event committee; and CI, confidence interval. 47 Although the reproducibility of the CEC process may be good, the identification of 47 additional ST events by the ACL compared with the CEC in this study suggests the criteria used by the CEC may not have been broad enough to capture all the definite ST events. It is also possible that the CEC had adjudicated these as probable or possible ST, whereas the ACL confirmed that they were definite ST. Although the ACL identified a substantial number of additional ST events compared with the CEC, the CEC itself identified only 7 (9.9%) additional ARC definite ST 32, 34, 35 The relatively low sensitivity of CEC adjudication in the detection of ST by the ARC criteria is supported by the gold standard of autopsy data, which demonstrates a specificity of 99% but a sensitivity of only 18% in the ascertainment of ST. 48 The discordance observed in this study was predominantly in 1 direction: ST detected by the ACL and not by the CEC. The CEC is limited by its inability to review the angiogram firsthand and by the quality of source documents. The specific end point itself, too, may be a factor in the sensitivity of a CEC. For example, MI can be identified based on electrocardiographic changes and quantification of the level of biomarkers. Such an end point aids LIs in providing the relevant information because the reporting of biomarkers is fairly objective. The definition of ARC definite ST used in the study requires angiographic evidence of a detected thrombus within 5 mm, proximally or distally, of the stented region. Although LIs tended to over report the presence of ST on the eCRF, the low number of events identified outside what was reported by LIs suggests there was overall underreporting of angiographic details in the source documents.
A systematic review of angiograms with possible ST events by an ACL would provide the CEC an independent assessment as to whether a given event met the angiographic criteria for ST. A similar strategy in identifying MI events has been successfully used by the event committees in the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) Platform and PLATO trials, who reviewed the plots of creatine kinasemyocardial band and troponin values in relation to time of all suspected events. 31, 32 The central review of angiograms may provide better agreement between the LIs and the CEC and may also improve the ability of the CEC to identify events not reported by the LI.
Limitations
This study was limited by missing data. Because this substudy was implemented late during the course of the trial, not all the angiograms identified as needing ACL review were retrieved by the end of the main TRACER trial. Of the 457 suspected cases of ST, 27.5% did not have angiographic films available for review, and 0.4% were not able to be evaluated by the CEC. The reason for missing data was not systematically addressed. However, LIs were required to deidentify angiograms before submitting them to the ACL. Also, some LIs were unable to deidentify films and could not submit them before the end of the study.
Conclusions
There was only moderate agreement between LIs, a CEC, and an ACL in assessing ST. The discordance was predominantly because of ST being detected more often by the ACL than the CEC.
In clinical trials where ST represents a key end point, a systematic review of available angiograms by a core laboratory is important to provide the CEC with an independent assessment of whether a given event met the angiographic criteria for ST, possibly improving the sensitivity and specificity of the CEC adjudication process.
